Quick Answer
GLP-1 medications like semaglutide and tirzepatide are injected subcutaneously into the abdomen (staying about two inches away from the navel), the front or outer thigh, or the back of the upper arm. FDA prescribing information for both compounds reports similar exposure across all three sites, so absorption is not a reason to favor one over another.12 Rotating the spot every week is the part that matters, since repeatedly injecting the same patch of tissue may lead to lipohypertrophy, a firm fatty buildup under the skin that research in insulin users links to erratic absorption.3 Defiant's Custom GLP-1 Protocol starts from $295/mo and includes in-clinic injection training, bi-weekly titration check-ins, and monthly body composition scans.
You can inject a GLP-1 into your abdomen, the front or outer part of your thigh, or the back of your upper arm. All three are approved in the FDA prescribing information for both semaglutide and tirzepatide, and the labels report similar drug exposure across all three.12 So the honest answer to "which spot works best" is that the choice matters far less than most people expect. What matters much more is whether you're moving the needle around week to week and whether your technique is decent.
That second part is where we spend most of our time with new patients at Defiant, because a surprising number of people arrive having been shipped a pen by a telehealth company with a one-page PDF and zero coaching.
- The three approved injection sites
- Does the site change how well it works?
- Why rotation is the part that actually matters
- Where you should not inject
- What's normal afterward, and what isn't
- The mistakes we see most often
- How we handle injection training at Defiant
- Key Takeaways
- Frequently Asked Questions
The Three Approved Injection Sites
Subcutaneous means the shot goes into the layer of fat between your skin and the muscle underneath. That layer has relatively few blood vessels and nerve endings compared to muscle, which is why the injection is usually painless and why the medication releases slowly rather than all at once. Three areas of the body have enough of that fat layer to work reliably.
| Site | Where exactly | Reach for self-injection | Notes |
|---|---|---|---|
| Abdomen | Anywhere on the belly except roughly two inches around the navel | Easiest | Largest surface area, so it gives you the most room to rotate |
| Thigh | Front and outer thigh, mid-way between hip and knee | Easy | Good backup site; skip it right before a hard leg day if it feels tender |
| Upper arm | Back of the arm, the fleshy area over the tricep | Hardest alone | Usually the site people use when someone else is helping |
The abdomen
Most people land here and stay here, and that's a perfectly good default. You've got a wide area to work with, the tissue is easy to pinch, and you can see exactly what you're doing without contorting yourself in a mirror. The one rule is to stay clear of the two-inch zone around your belly button, where the tissue is tougher and less predictable.1
If you carry most of your weight around your midsection, you have plenty of real estate here. If you don't, you may find you need to pinch a little more deliberately to make sure you're in fat and not muscle.
The thigh
The front and outer thigh works just as well and gives you somewhere to go when your abdomen feels overworked. Aim for the meaty part roughly halfway between your hip and your knee, and stay off the inner thigh, where the tissue is thinner and more sensitive. Some patients tell us thigh injections sting slightly more than abdominal ones. That's common and not a sign anything is wrong.
The back of the upper arm
This one is approved and perfectly effective, but reaching around to the back of your own arm while holding a pen steady is genuinely awkward. If you live with a partner who's willing to help, it's a great rotation option. If you're injecting solo every week, you'll probably find yourself defaulting back to the abdomen and thigh, and that's fine.
Does the Site Change How Well It Works?
Not in a way you'll notice on the scale. The FDA prescribing information for semaglutide and for tirzepatide both state that similar exposure is achieved with subcutaneous administration in the abdomen, thigh, or upper arm.12 Eli Lilly ran a dedicated crossover study comparing thigh and upper arm against abdomen for a 5 mg tirzepatide dose across two different BMI groups, which is where a lot of that labeling language comes from.4
There are small measurable differences in how quickly the drug shows up in the bloodstream, because abdominal fat has somewhat higher blood flow than the thigh. But these medications are built for slow release, and the timeline blunts the difference. Tirzepatide reaches peak plasma concentration somewhere between 8 and 72 hours after a dose, and semaglutide takes one to three days.12 When a drug takes days to peak and roughly a week to clear half of itself, a modest difference in the first few hours of absorption gets smoothed out.
The practical takeaway: pick the sites you can reach comfortably and consistently, then focus your attention on rotation and technique.
Why Rotation Is the Part That Actually Matters
Injecting into the same square inch of skin over and over may cause lipohypertrophy, a rubbery, thickened lump of fat and scar tissue that builds up under the surface. It's usually painless, which is exactly why people miss it. You'll feel it before you see it, and often only if you go looking.
The best data we have on this comes from insulin users rather than GLP-1 users, since insulin has been injected daily for decades and GLP-1s are once weekly. A study of 430 insulin-injecting patients found lipohypertrophy in 64.4% of them, and among the patients who had it, 98% either weren't rotating sites or were rotating incorrectly.3 Among patients who rotated properly, only 5% developed it. Those same patients with lipohypertrophy showed substantially more unexplained hypoglycemia and glycemic variability, which researchers attribute to unpredictable absorption from damaged tissue.3
A weekly GLP-1 injection puts far less cumulative stress on your skin than four daily insulin shots, so nobody should read that as an alarm bell. Research suggests the underlying mechanism is the same, though, and a year of once-weekly dosing is still 52 injections. Rotating costs you nothing.
A rotation system that's easy to stick to
Overcomplicating this is the fastest way to abandon it. Here's a simple approach that works:
- Split your abdomen into four quadrants. Upper left, upper right, lower left, lower right, all staying about two inches clear of the navel.
- Move one quadrant per week, so you're back at the starting quadrant roughly once a month.
- Within a quadrant, shift at least an inch from wherever you went last time you were there.
- Add your thighs to the cycle if you want more spacing, which stretches your return interval out to six weeks or more.
- Write it down. A note in your phone next to your dose reminder takes three seconds and beats trying to remember where you went 28 days ago.
Some patients keep an index card on the fridge. Others use the notes app. The system doesn't matter as much as having one, because "I'll just remember" reliably turns into the same two inches of skin every week.
Where You Should Not Inject
Skip any area of skin that is:
- Bruised, red, tender, swollen, or broken
- Scarred, including surgical scars and old piercings
- Covered by a mole, a tattoo you'd rather not distort, or a large stretch mark
- Within about two inches of your navel
- Already firm or lumpy from previous injections, which is the tissue you're trying to let recover
- On your inner thigh, the front of your arm, your lower back, or your buttocks, none of which are approved sites for these medications
If you find a lump, leave that area alone entirely and mention it at your next check-in. Most of these resolve on their own once they get a break, but a provider should take a look.
What's Normal Afterward, and What Isn't
Mild redness, a small bump, some itching, or a bit of bruising at the site is common and usually clears within a day or two. A pinprick of blood happens sometimes and doesn't mean anything went wrong. A drop of liquid escaping after you withdraw usually means the needle came out a beat too early, and the amount lost is generally negligible, though you should still tell your provider rather than redosing on your own.
Call your provider if you see a reaction that keeps expanding, gets warm and increasingly painful over several days, or comes with fever. Get emergency care for any sign of a severe allergic reaction, including trouble breathing, swelling of the face or throat, or a rash spreading across your body.
None of the above is a substitute for talking to your own provider about what you're experiencing. If something feels off, ask. Our patients have nurse access between visits precisely so these questions don't sit unanswered for a week.
The Mistakes We See Most Often
Injecting into the same spot forever. By a mile, the most common one. People find a spot that doesn't hurt and camp there.
Injecting cold medication. Nothing dangerous about it, but it stings more, and pain makes people dread the shot, and dread makes people skip doses.
Not writing down the day. Both semaglutide and tirzepatide are once-weekly, and the day should stay consistent. If you do slip, ask your provider what to do rather than guessing, since the right move depends on which compound you're on and how long it's been.
Reusing needles. Needles dull after one use, which makes the next injection hurt more and may increase tissue trauma. One needle, one injection, then the sharps container.
How We Handle Injection Training at Defiant
Patients on our Custom GLP-1 Protocol do their first injection in the clinic in Lisle with a provider watching, not alone at their kitchen table with a YouTube video open. We walk through site selection, the pinch, the angle, the hold, and we build the rotation plan with you before you leave.
From there, check-ins run every two weeks rather than monthly, which is the same cadence we use for titration decisions. That schedule catches technique drift early, and it means an injection question doesn't have to wait 30 days for an answer. Monthly Styku 3D body composition scans track what's happening to fat versus lean mass, since the scale alone hides a lot on a GLP-1.
The program starts from $295/mo and covers medication, provider oversight, bi-weekly titration check-ins, monthly body composition scans, and nurse access between visits. We're at 5100 Lincoln Ave in Lisle, and we see patients from Naperville, Downers Grove, Wheaton, Bolingbrook, Lombard, and across the western suburbs.
- The abdomen, front and outer thigh, and back of the upper arm are the three approved subcutaneous injection sites for semaglutide and tirzepatide.12
- FDA prescribing information for both compounds reports similar exposure across all three sites, so site choice is a comfort and convenience decision.12
- Rotating the exact spot each week matters more than which region you choose, because repeated injections into one area may cause lipohypertrophy and unpredictable absorption.3
- In insulin users, 98% of patients with lipohypertrophy either didn't rotate or rotated incorrectly, compared with a 5% rate among correct rotators.3
- Stay about two inches away from the navel, avoid scarred or bruised skin, and never inject into tissue that already feels firm or lumpy.
Frequently Asked Questions
Learn It Right the First Time.
Every Defiant GLP-1 patient does their first injection in the clinic with a provider, then checks in every two weeks for titration and technique. Custom GLP-1 Protocol from $295/mo, including medication, monthly body composition scans, and nurse access between visits.
Keep Reading
Last updated August 18, 2026.
References
- Semaglutide injection, for subcutaneous use. Prescribing Information. U.S. Food and Drug Administration. 2025. FDA label (PDF)
- Tirzepatide injection, for subcutaneous use. Prescribing Information. U.S. Food and Drug Administration. 2025. FDA label (PDF)
- Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes & Metabolism. 2013;39(5):445-453. PubMed
- A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes. ClinicalTrials.gov, NCT04050670. Trial record
- Safely Using Sharps (Needles and Syringes) at Home, at Work and on Travel. U.S. Food and Drug Administration. FDA guidance